Payment overview · 2025
General Payments
$719.57
39 reported records · 16 companies
Healthcare provider profile · identity verified
Edwin Aziegbe Avbuere, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GREENSBORO, NC · NPI 1013019470
Verified facts
What the public records show
CMS Open Payments records show Edwin Aziegbe Avbuere, MD received $719.57 in general payments during 2025 across 39 reported records.
Lilly USA, LLC accounted for 15.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Kerendia, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 243 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 243 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 237 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 256 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $112.80 | 15.7% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.55 | 10.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $68.36 | 9.5% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $57.76 | 8.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $57.75 | 8.0% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $51.78 | 7.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $51.42 | 7.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.85 | 5.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $32.30 | 4.5% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $29.47 | 4.1% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.84 | 4.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $27.29 | 3.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.86 | 3.3% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $20.81 | 2.9% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.74 | 2.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.99 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $719.57 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $94.61 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $80.30 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $68.36 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $58.04 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $57.76 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $57.75 | 3 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $51.78 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $51.42 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $39.45 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.10 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $29.47 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $28.84 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $27.29 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.86 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 243 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 237 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 256 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 132 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
89 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
145 | 32 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
243 | 53 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
88 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
132 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
243 | 53 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
237 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
99 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
256 | 37 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 992 | 239 |
| Atorvastatin Calcium | Atorvastatin Calcium | 787 | 189 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 666 | 153 |
| Gabapentin | Gabapentin | 637 | 168 |
| Metformin Hcl | Metformin Hcl | 582 | 137 |
| Tizanidine Hcl | Tizanidine Hcl | 482 | 140 |
| Furosemide | Furosemide | 472 | 124 |
| Pantoprazole Sodium | Pantoprazole Sodium | 464 | 99 |
| Diclofenac Sodium | Diclofenac Sodium | 456 | 146 |
| Omeprazole | Omeprazole | 422 | 75 |
| Fluticasone Propionate | Fluticasone Propionate | 399 | 132 |
| Losartan Potassium | Losartan Potassium | 375 | 93 |
| Simvastatin | Simvastatin | 335 | 79 |
| Ibuprofen | Ibuprofen | 311 | 63 |
| Meloxicam | Meloxicam | 301 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 298 | 63 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 295 | 82 |
| Famotidine | Famotidine | 294 | 71 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 284 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 266 | 58 |
| Ozempic | Semaglutide | 256 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 255 | 75 |
| Potassium Chloride | Potassium Chloride | 251 | 66 |
| Lisinopril | Lisinopril | 246 | 54 |
| Jardiance | Empagliflozin | 243 | 53 |
| Mounjaro | Tirzepatide | 237 | 31 |
| Trazodone Hcl | Trazodone Hcl | 231 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 227 | 44 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 203 | 80 |
| Linzess | Linaclotide | 195 | 39 |
| Allopurinol | Allopurinol | 183 | 49 |
| Glimepiride | Glimepiride | 175 | 32 |
| Prednisone | Prednisone | 166 | 83 |
| Montelukast Sodium | Montelukast Sodium | 161 | 33 |
| Mirtazapine | Mirtazapine | 147 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 146 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 146 | 25 |
| Symbicort | Budesonide/Formoterol Fumarate | 145 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 138 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 134 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 132 | 27 |
| Carvedilol | Carvedilol | 128 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 30 |
| Alprazolam | Alprazolam | 126 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 121 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 114 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 33 |
| Pregabalin | Pregabalin | 106 | 32 |
| Sertraline Hcl | Sertraline Hcl | 106 | 26 |
| Celecoxib | Celecoxib | 101 | 23 |
| Azithromycin | Azithromycin | 100 | 85 |
| Hydralazine Hcl | Hydralazine Hcl | 99 | 27 |
| Trulicity | Dulaglutide | 99 | 23 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 98 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 95 | 21 |
| Farxiga | Dapagliflozin Propanediol | 89 | 22 |
| Januvia | Sitagliptin Phosphate | 89 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 88 | 25 |
| Eliquis | Apixaban | 88 | 28 |
| Ventolin Hfa | Albuterol Sulfate | 88 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 17 |
| Xarelto | Rivaroxaban | 86 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 85 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 81 | 23 |
| Tramadol Hcl | Tramadol Hcl | 81 | 36 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 80 | 22 |
| Fluconazole | Fluconazole | 78 | 35 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 77 | 14 |
| Meclizine Hcl | Meclizine Hcl | 77 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 73 | 59 |
| Buspirone Hcl | Buspirone Hcl | 71 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 71 | 20 |
| Diazepam | Diazepam | 70 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 69 | 55 |
| Promethazine Hcl | Promethazine Hcl | 69 | 11 |
| Risperidone | Risperidone | 69 | 13 |
| Methocarbamol | Methocarbamol | 65 | 23 |
| Colchicine | Colchicine | 64 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 22 |
| Lidocaine | Lidocaine | 63 | 18 |
| Ondansetron Odt | Ondansetron | 63 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | suppressed |
| Topiramate | Topiramate | 58 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 57 | 13 |
| Alendronate Sodium | Alendronate Sodium | 55 | 13 |
| Baclofen | Baclofen | 51 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 51 | suppressed |
| Nitroglycerin | Nitroglycerin | 49 | 17 |
| Spironolactone | Spironolactone | 49 | 14 |
| Olanzapine | Olanzapine | 48 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 47 | 11 |
| Desmopressin Acetate | Desmopressin Acetate | 45 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Glipizide | Glipizide | 44 | 16 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 43 | 15 |
| Nabumetone | Nabumetone | 43 | 12 |
| Atenolol | Atenolol | 42 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 42 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 39 | 18 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 38 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 38 | suppressed |
| Levemir Flexpen | Insulin Detemir | 37 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 35 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 34 | suppressed |
| Mupirocin | Mupirocin | 33 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 32 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 32 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 32 | 11 |
| Torsemide | Torsemide | 32 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 25 |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 23 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 22 | 13 |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 16 |
| Folic Acid | Folic Acid | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Epinephrine | Epinephrine | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Dalfampridine Er | Dalfampridine | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Sprintec | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Ztlido | Lidocaine | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $719.57 · 39 records | Lilly USA, LLC | ACCRUFER, AIRSUPRA, CAPLYTA, COBENFY, FANAPT, GEMTESA, GVOKE HYPOPEN, JARDIANCE, Kerendia, Korlym, MOUNJARO, Ozempic, RELISTOR, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, Wegovy, XIFAXAN, YUPELRI, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error